CO2018009604A2 - Compuesto heterocíclico - Google Patents
Compuesto heterocíclicoInfo
- Publication number
- CO2018009604A2 CO2018009604A2 CONC2018/0009604A CO2018009604A CO2018009604A2 CO 2018009604 A2 CO2018009604 A2 CO 2018009604A2 CO 2018009604 A CO2018009604 A CO 2018009604A CO 2018009604 A2 CO2018009604 A2 CO 2018009604A2
- Authority
- CO
- Colombia
- Prior art keywords
- pain
- disease
- present
- heterocyclic compound
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
RESUMEN La presente invención proporciona un compuesto que tiene una acción inhibidora de MAGL, y útil como un agente para la profilaxis o tratamiento de enfermedades neurodegenerativas (por ejemplo, enfermedad de Alzheimer, enfermedad de Parkinson, enfermedad de Huntington, esclerosis lateral amiotrófica, lesión cerebral traumática, glaucoma, esclerosis múltiple, etc.), trastorno de ansiedad, dolores (por ejemplo, dolor inflamatorio, dolor canceroso, dolor neurogénico, etc.), epilepsia, depresión y similares. La presente invención se refiere a un compuesto representado por la fórmula (I): donde cada símbolo es como se define en la memoria descriptiva, o una de sus sales.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016071181 | 2016-03-31 | ||
PCT/JP2017/014597 WO2017171100A1 (en) | 2016-03-31 | 2017-03-30 | Heterocyclic compound |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2018009604A2 true CO2018009604A2 (es) | 2018-12-14 |
Family
ID=58707980
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2018/0009604A CO2018009604A2 (es) | 2016-03-31 | 2018-09-13 | Compuesto heterocíclico |
Country Status (28)
Country | Link |
---|---|
US (1) | US10323026B2 (es) |
EP (1) | EP3436444B1 (es) |
JP (1) | JP6788683B2 (es) |
KR (1) | KR102388440B1 (es) |
CN (1) | CN109715613B (es) |
AR (1) | AR108012A1 (es) |
AU (1) | AU2017245125B2 (es) |
BR (1) | BR112018068538B1 (es) |
CA (1) | CA3019298C (es) |
CL (1) | CL2018002777A1 (es) |
CO (1) | CO2018009604A2 (es) |
DK (1) | DK3436444T3 (es) |
EA (1) | EA036637B1 (es) |
EC (1) | ECSP18081909A (es) |
ES (1) | ES2804580T3 (es) |
IL (1) | IL261488B (es) |
MX (1) | MX2018011729A (es) |
MY (1) | MY194647A (es) |
PE (1) | PE20190409A1 (es) |
PH (1) | PH12018502101A1 (es) |
PL (1) | PL3436444T3 (es) |
SG (1) | SG11201807539UA (es) |
TN (1) | TN2018000299A1 (es) |
TW (1) | TWI738753B (es) |
UA (1) | UA122435C2 (es) |
UY (1) | UY37174A (es) |
WO (1) | WO2017171100A1 (es) |
ZA (1) | ZA201807249B (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
MX2018011784A (es) | 2016-03-31 | 2019-02-13 | Janssen Pharmaceuticals Inc | Derivados de indol sustituidos como inhibidores de la replicacion virica del dengue. |
WO2017170830A1 (ja) | 2016-03-31 | 2017-10-05 | 武田薬品工業株式会社 | 複素環化合物 |
WO2017167953A1 (en) | 2016-03-31 | 2017-10-05 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
BR112018068956A2 (pt) | 2016-04-01 | 2019-01-22 | Janssen Pharmaceuticals Inc | derivados do composto indol substituídos como inibidores da replicação viral da dengue |
JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
PE20200342A1 (es) | 2017-05-22 | 2020-02-14 | Janssen Pharmaceuticals Inc | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue |
ES2929667T3 (es) | 2017-05-22 | 2022-11-30 | Janssen Pharmaceuticals Inc | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue |
MX2020002251A (es) | 2017-08-29 | 2020-07-20 | Lundbeck La Jolla Research Center Inc | Compuestos espirociclicos y sus metodos de preparacion y uso. |
MX2020007318A (es) | 2017-09-29 | 2020-08-24 | Takeda Pharmaceuticals Co | Compuesto heterociclico. |
AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
EP3717477B1 (en) | 2017-11-28 | 2022-07-20 | F. Hoffmann-La Roche AG | New heterocyclic compounds |
WO2019134985A1 (en) | 2018-01-08 | 2019-07-11 | F. Hoffmann-La Roche Ag | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
MA53220A (fr) * | 2018-08-13 | 2021-11-17 | Hoffmann La Roche | Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de monoacylglycérol lipase |
EP3837263A1 (en) | 2018-08-13 | 2021-06-23 | F. Hoffmann-La Roche AG | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
EP4028403B1 (en) | 2019-09-12 | 2023-11-22 | F. Hoffmann-La Roche AG | 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors |
EP4103557A1 (en) * | 2020-02-10 | 2022-12-21 | Janssen Pharmaceutica NV | Monoacylglycerol lipase modulators |
US11505546B2 (en) | 2020-03-26 | 2022-11-22 | Janssen Pharmaceutica Nv | Azaspirocycles as monoacylglycerol lipase modulators |
CA3176113A1 (en) * | 2020-03-26 | 2021-09-30 | Janssen Pharmaceutica Nv | Aminocyclobutanes as monoacylglycerol lipase modulators |
JP2023518515A (ja) * | 2020-03-26 | 2023-05-01 | ヤンセン ファーマシューティカ エヌ.ベー. | モノアシルグリセロールリパーゼ調節因子としてのアリールピペリジン |
TW202229255A (zh) | 2020-11-13 | 2022-08-01 | 丹麥商H 朗德貝克公司 | Magl抑制劑 |
KR20240005747A (ko) | 2021-05-08 | 2024-01-12 | 얀센 파마슈티카 엔브이 | 치환된 스피로 유도체 |
KR20240046538A (ko) | 2021-08-09 | 2024-04-09 | 얀센 파마슈티카 엔브이 | 자폐증 스펙트럼 장애에 사용하기 위한 모노아실글리세롤 리파제 조절제 |
CN115925699B (zh) * | 2022-02-25 | 2023-10-03 | 南京知和医药科技有限公司 | 具有镇痛活性的稠环化合物及其制备方法与用途 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ535121A (en) * | 2002-03-13 | 2007-02-23 | Schering Corp | NK1 antagonists |
TW200902007A (en) * | 2007-05-25 | 2009-01-16 | Astrazeneca Ab | Spirocyclopropyl piperidine derivatives |
US8435977B2 (en) | 2009-04-22 | 2013-05-07 | Janssen Pharmaceutica, Nv | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors |
EP2421848A1 (en) | 2009-04-22 | 2012-02-29 | Janssen Pharmaceutica N.V. | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
WO2010124121A1 (en) | 2009-04-22 | 2010-10-28 | Jansen Pharmaceutica Nv | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitor |
TW201103914A (en) | 2009-04-22 | 2011-02-01 | Janssen Pharmaceutica Nv | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors |
AU2011296068B2 (en) | 2010-09-03 | 2015-07-09 | Janssen Pharmaceutica Nv | Di-azetidinyl diamide as monoacylglycerol lipase inhibitors |
EP2621918A1 (en) | 2010-09-27 | 2013-08-07 | Janssen Pharmaceutica, N.V. | Oxopiperazine-azetidine amides and oxodiazepine-azetidine amides as monoacylglycerol lipase inhibitors |
CN103260703A (zh) * | 2010-10-22 | 2013-08-21 | 詹森药业有限公司 | 作为单酰甘油脂肪酶抑制剂的哌啶-4-基-氮杂环丁烷二酰胺 |
US8513423B2 (en) | 2010-10-22 | 2013-08-20 | Janssen Pharmaceutica, Nv | Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors |
KR20140068241A (ko) | 2011-09-30 | 2014-06-05 | 얀센 파마슈티카 엔.브이. | 대사 질환 및 관련 장애의 치료를 위한 모노아실글리세롤 리파제 억제제 |
EP2760450A1 (en) | 2011-09-30 | 2014-08-06 | Janssen Pharmaceutica, N.V. | Monoacylglycerol lipase inhibitors for the treatment of metabolic diseases and related disorders |
EP3698782B1 (en) * | 2012-01-06 | 2024-05-15 | H. Lundbeck A/S | Carbamate compounds for use in therapy |
JP6454349B2 (ja) | 2013-12-26 | 2019-01-16 | 武田薬品工業株式会社 | モノアシルグリセロールリパーゼ(magl)阻害剤としての4−(ピペラジン−1−イル)−ピロリジン−2−オン化合物 |
US10314841B2 (en) * | 2014-01-09 | 2019-06-11 | Merck Patent Gmbh | Substituted pyrazoles as IRAK inhibitors |
WO2016158956A1 (ja) | 2015-03-30 | 2016-10-06 | 武田薬品工業株式会社 | 複素環化合物 |
-
2017
- 2017-03-30 BR BR112018068538-0A patent/BR112018068538B1/pt active IP Right Grant
- 2017-03-30 EP EP17723531.4A patent/EP3436444B1/en active Active
- 2017-03-30 ES ES17723531T patent/ES2804580T3/es active Active
- 2017-03-30 AR ARP170100789A patent/AR108012A1/es unknown
- 2017-03-30 DK DK17723531.4T patent/DK3436444T3/da active
- 2017-03-30 SG SG11201807539UA patent/SG11201807539UA/en unknown
- 2017-03-30 CA CA3019298A patent/CA3019298C/en active Active
- 2017-03-30 PL PL17723531T patent/PL3436444T3/pl unknown
- 2017-03-30 TW TW106110783A patent/TWI738753B/zh active
- 2017-03-30 UA UAA201810731A patent/UA122435C2/uk unknown
- 2017-03-30 MX MX2018011729A patent/MX2018011729A/es active IP Right Grant
- 2017-03-30 UY UY0001037174A patent/UY37174A/es not_active Application Discontinuation
- 2017-03-30 PE PE2018001848A patent/PE20190409A1/es unknown
- 2017-03-30 WO PCT/JP2017/014597 patent/WO2017171100A1/en active Application Filing
- 2017-03-30 MY MYPI2018703541A patent/MY194647A/en unknown
- 2017-03-30 KR KR1020187030584A patent/KR102388440B1/ko active IP Right Grant
- 2017-03-30 CN CN201780032516.6A patent/CN109715613B/zh active Active
- 2017-03-30 US US15/474,192 patent/US10323026B2/en active Active
- 2017-03-30 AU AU2017245125A patent/AU2017245125B2/en active Active
- 2017-03-30 EA EA201892215A patent/EA036637B1/ru not_active IP Right Cessation
- 2017-03-30 JP JP2018549603A patent/JP6788683B2/ja active Active
- 2017-03-30 TN TNP/2018/000299A patent/TN2018000299A1/en unknown
-
2018
- 2018-08-30 IL IL261488A patent/IL261488B/en active IP Right Grant
- 2018-09-13 CO CONC2018/0009604A patent/CO2018009604A2/es unknown
- 2018-09-28 PH PH12018502101A patent/PH12018502101A1/en unknown
- 2018-09-28 CL CL2018002777A patent/CL2018002777A1/es unknown
- 2018-10-30 EC ECSENADI201881909A patent/ECSP18081909A/es unknown
- 2018-10-30 ZA ZA2018/07249A patent/ZA201807249B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018009604A2 (es) | Compuesto heterocíclico | |
CO2020003932A2 (es) | Compuesto heterocíclico | |
DOP2018000031A (es) | DERIVADOS DE 1,1,1-TRIFLUORO-3-HIDROXIPROPAN-2-IL CARBAMATO y DERIVADOS DE 1,1,1-TRIFLUORO-4-HIDROXIBUTAN-2-IL CARBAMATO COMO INHIBIDORES DE MAGL | |
UY36071A (es) | Compuesto de ciclopropanamina y sus usos | |
DOP2016000195A (es) | Compuestos | |
CR20180452A (es) | Moduladores alostéricos de receptores de acetilcolina nicotícos | |
BR112015026660A2 (pt) | ligas metálicas aperfeiçoadas para dispositivos médicos | |
EA201690501A1 (ru) | Новые композиции для лечения неврологических расстройств | |
BR112018069533A2 (pt) | tratamento de condições alérgicas oculares com ciclodextrinas | |
CO2017004465A2 (es) | 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
BR112018010564A2 (pt) | composições farmacêuticas compreendendo levodopa amida e usos das mesmas | |
BR112018071560A2 (pt) | compostos e métodos para tratar condições neurológicas e cardiovasculares | |
UY36868A (es) | Composiciones para tratamiento de enfermedades mediadas por interleuquina 5 (il-5) | |
CL2019000534A1 (es) | Inhibidores de cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades. | |
WO2014160871A8 (en) | Methods and agents for treating alzheimer's disease | |
AR112472A1 (es) | Forma de sales cristalinas de amida de levodopa y métodos para elaborarlas y usarlas | |
BR112017025263A2 (pt) | método para o tratamento de doença neurológica | |
MX2021008819A (es) | Analogos de cisteamina resistentes a la ado y sus usos. | |
BR112016016098A2 (pt) | Compostos orgânicos | |
BR112019004864A2 (pt) | inibidores cetona de lisina gingipain | |
AR120165A1 (es) | Composiciones de oligonucleótidos y métodos de uso de las mismas | |
EA201792076A1 (ru) | Методы и композиции для внутривенного введения фумаратов для лечения неврологических заболеваний | |
UY35603A (es) | Compuesto heterocíclico |